摘要
心脏机械瓣膜置换术后早期机体处于低凝状态,抗凝并发症发生率较高。抗凝治疗早期存在华法令“抗凝真空”,是否需要其他辅助抗凝方法,目前尚未规范化、科学化。,凝血因子,凝血酶原片段1+2(F1+2),尿纤维蛋白肽A(UFPA)和国际标准比值(INR)能正确反映48～72h以后的抗凝强度。合理的早期抗凝治疗和准确及时的监测方法对减少并发症、提高患者术后生存率和生活质量具有重要意义。
The body is at a hypo-coagulation status after the heart mechanic valve prosthesis replacement operation, and the incidence of anticoagulation complications is rather high because of that administration of warfarin may result in “anticoagulation vacuum” at an early stage. Moreover, the necessary application of other anticoagulation methods assisting the employment of warfarin have still not been scientifically normalized. Blood coagulation factor Ⅱ,Ⅶ, prothrombin fragment_~1+2 (F_~1+2 ), urine fibrimopeptide A (UFPA) , and International Normalized Ratio(INR), could exactly reflect the anticoagulation intensity 48-72 hours after the replacement operation,reasonable use of anticoagulant therapy as well as accurate and in-time monitoring methods is significant to reduce complications,elevate survival rate, and improve quality of life.
出处
《中国胸心血管外科临床杂志》
CAS
2005年第2期110-113,共4页
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
